{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:00:08Z","timestamp":1779192008438,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer S.r.l."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study is describing subjects with migraine interrupting or not receiving triptans for acute treatment and providing a national-level estimate of people who might benefit from different therapeutic approaches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective analysis using IQVIA Longitudinal Patient Database. Starting from 18\u2009+\u2009years old individuals with migraine, we selected two cohorts: subjects with triptans prescriptions before and no triptans prescriptions after Index Date (triptan withdraw) and subjects without triptans prescriptions both before and after Index Date (no triptan prescriptions). Index Date was the first record of a health encounter for migraine in 2019. Individuals with cardiovascular disease (CVD) within no triptan prescriptions group were also quantified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Triptan withdraw and no triptan prescriptions cohorts numbered 605 and 3270, respectively, 5% and 29% of subjects with migraine. Mean age was 47 and 51\u00a0years respectively; women were more represented (~\u200980%). Hypertension and thyroid disease were most frequent comorbidities; non-steroidal anti-inflammatory drugs were among most frequently recorded treatments. Subjects with CVD within no triptan prescriptions cohort were 621 and with triptan withdraw cohort subjects represented the basis to estimate those who might benefit from alternative options for the acute treatment of migraine, who were around 60,000 and accounted for 11% of subjects seeking primary care due to migraine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This analysis provides a real-word estimate of Italian people that might benefit from different therapeutic approaches as an alternative to triptans, which sometimes might be not effective and\/or poorly tolerated. Such estimate should be intended as the lower limit of a wider range due to strict criteria adopted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-024-07493-w","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T20:01:52Z","timestamp":1711569712000},"page":"4427-4435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute treatment of migraine: quantifying the unmet need through real-world data in Italy"],"prefix":"10.1007","volume":"45","author":[{"given":"Simona","family":"Sacco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Di Ciaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Di Virgilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-6380","authenticated-orcid":false,"given":"Valeria","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"7493_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15256\/joc.2017.7.114","volume":"7","author":"G McLean","year":"2017","unstructured":"McLean G, Mercer SW (2017) Chronic migraine, comorbidity, and socioeconomic deprivation: cross-sectional analysis of a large nationally representative primary care database. J Comorbidity 7:89\u201395","journal-title":"J Comorbidity"},{"key":"7493_CR2","first-page":"A08200592","volume":"68","author":"AH Snoer","year":"2021","unstructured":"Snoer AH, H\u00f8st C, D\u00f8mgaard M, Hansen JM (2021) Frequent or chronic migraine negatively impacts personal, social and professional life. Dan Med J 68:A08200592","journal-title":"Dan Med J"},{"key":"7493_CR3","doi-asserted-by":"crossref","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; On behalf of Lifting The Burden: the Global Campaign against Headache (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137.\u00a0https:\/\/doi.org\/10.1186\/s10194-020-01208-0","DOI":"10.1186\/s10194-020-01208-0"},{"key":"7493_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM et al (2015) The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 35:563\u2013578","journal-title":"Cephalalgia"},{"key":"7493_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/13696998.2021.1925557","volume":"24","author":"P Martelletti","year":"2021","unstructured":"Martelletti P et al (2021) Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey. J Med Econ 24:717\u2013726","journal-title":"J Med Econ"},{"key":"7493_CR6","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1080\/03007995.2019.1602032","volume":"35","author":"E Agostoni","year":"2019","unstructured":"Agostoni E et al (2019) Real-world insights on the management of migraine patients: an Italian nationwide study. Curr Med Res Opin 35:1545\u20131554","journal-title":"Curr Med Res Opin"},{"key":"7493_CR7","doi-asserted-by":"publisher","first-page":"033310242211437","DOI":"10.1177\/03331024221143773","volume":"43","author":"I de Boer","year":"2023","unstructured":"de Boer I, Verhagen IE, Souza MNP, Ashina M (2023) Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia 43:033310242211437","journal-title":"Cephalalgia"},{"key":"7493_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23:133","journal-title":"J Headache Pain"},{"key":"7493_CR9","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","volume":"37","author":"E Leroux","year":"2020","unstructured":"Leroux E et al (2020) Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther 37:4765\u20134796","journal-title":"Adv Ther"},{"key":"7493_CR10","unstructured":"Istituto di ricerca della SIMG. XIV report Health Search (2022) Societ\u00e0 Italiana di Medicina Generale e delle Cure Primarie. Available at \nhttps:\/\/report.healthsearch.it\/XV_REPORT_HS.pdf?anno=2023. Accessed 10 Aug 2023"},{"key":"7493_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41533-017-0051-9","volume":"27","author":"F Di Marco","year":"2017","unstructured":"Di Marco F et al (2017) Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study. NPJ Prim Care Respir Med 27:51","journal-title":"NPJ Prim Care Respir Med"},{"key":"7493_CR12","doi-asserted-by":"publisher","unstructured":"Di Marco F et al (2021) The burden of short-acting \u03b22-agonist use in asthma: is there an Italian Case? An Update from SABINA Program. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-021-01772-0","DOI":"10.1007\/s12325-021-01772-0"},{"key":"7493_CR13","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1080\/03007995.2022.2096352","volume":"38","author":"M Volpe","year":"2022","unstructured":"Volpe M, Pegoraro V, Peduto I, Heiman F, Meto S (2022) Extemporaneous combination therapy with nebivolol\/zofenopril in hypertensive patients: usage in Italy. Curr Med Res Opin 38:1673\u20131681","journal-title":"Curr Med Res Opin"},{"key":"7493_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2174\/1570159X20666220411092813","volume":"21","author":"M Di Nicola","year":"2023","unstructured":"Di Nicola M et al (2023) Adherence to, and persistence of, antidepressant therapy in patients with major depressive disorder: results from a population-based study in Italy. Curr Neuropharmacol 21:727\u2013739","journal-title":"Curr Neuropharmacol"},{"key":"7493_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1080\/03007995.2017.1335191","volume":"33","author":"P Katz","year":"2017","unstructured":"Katz P, Pegoraro V, Liedgens H (2017) Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster. Curr Med Res Opin 33:1481\u20131489","journal-title":"Curr Med Res Opin"},{"key":"7493_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/03007995.2023.2182530","volume":"39","author":"A Padovani","year":"2023","unstructured":"Padovani A, Falato S, Pegoraro V (2023) Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data. Curr Med Res Opin 39:567\u2013577","journal-title":"Curr Med Res Opin"},{"key":"7493_CR17","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW et al (2020) Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health 11:215013272096368","journal-title":"J Prim Care Community Health"},{"key":"7493_CR18","unstructured":"ISTAT. Istituto Nazionale di Statistica. www.istat.it.\u00a0Accessed 10 Aug 2023"},{"key":"7493_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1526-4610.2009.01458.x","volume":"49","author":"NT Mathew","year":"2009","unstructured":"Mathew NT et al (2009) Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache J Head Face Pain 49:971\u2013982","journal-title":"Headache J Head Face Pain"},{"key":"7493_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10194-008-0020-3","volume":"9","author":"A Panconesi","year":"2008","unstructured":"Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R (2008) Triptans in the Italian population: a drug utilization study and a literature review. J Headache Pain 9:71\u201376","journal-title":"J Headache Pain"},{"key":"7493_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/0333102420905307","volume":"40","author":"RB Lipton","year":"2020","unstructured":"Lipton RB et al (2020) Acute treatment patterns in patients with migraine newly initiating a triptan. Cephalalgia 40:437\u2013447","journal-title":"Cephalalgia"},{"key":"7493_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/j.1468-2982.2007.01401.x","volume":"27","author":"E Pavone","year":"2007","unstructured":"Pavone E, Banfi R, Vaiani M, Panconesi A (2007) Patterns of triptans use: a study based on the records of a community pharmaceutical department. Cephalalgia Int J Headache 27:1000\u20131004","journal-title":"Cephalalgia Int J Headache"},{"key":"7493_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12883-021-02451-x","volume":"21","author":"AM Deighton","year":"2021","unstructured":"Deighton AM et al (2021) The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review. BMC Neurol 21:425","journal-title":"BMC Neurol"},{"key":"7493_CR24","doi-asserted-by":"publisher","first-page":"e038972","DOI":"10.1136\/bmjopen-2020-038972","volume":"10","author":"V Orlando","year":"2020","unstructured":"Orlando V, Mucherino S, Monetti VM, Trama U, Menditto E (2020) Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study. BMJ Open 10:e038972","journal-title":"BMJ Open"},{"key":"7493_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-019-1027-7","volume":"20","author":"C Piccinni","year":"2019","unstructured":"Piccinni C et al (2019) A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain 20:74","journal-title":"J Headache Pain"},{"key":"7493_CR26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1468-2982.2008.01666.x","volume":"28","author":"W Stewart","year":"2008","unstructured":"Stewart W, Wood C, Reed M, Roy J, Lipton R (2008) Cumulative lifetime migraine incidence in women and men. Cephalalgia 28:1170\u20131178","journal-title":"Cephalalgia"},{"key":"7493_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","volume":"391","author":"DW Dodick","year":"2018","unstructured":"Dodick DW (2018) Migraine. The Lancet 391:1315\u20131330","journal-title":"The Lancet"},{"key":"7493_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343\u2013349","journal-title":"Neurology"},{"key":"7493_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.numecd.2022.11.014","volume":"33","author":"J Zhang","year":"2023","unstructured":"Zhang J et al (2023) Association between migraine or severe headache and hypertension among US adults: a cross-sectional study. Nutr Metab Cardiovasc Dis NMCD 33:350\u2013358","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"key":"7493_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15753","author":"S Tasnim","year":"2023","unstructured":"Tasnim S (2023) Nyholt DR (2023) Migraine and thyroid dysfunction: co-occurrence, shared genes, and biological mechanisms. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15753","journal-title":"Eur J Neurol"},{"key":"7493_CR31","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2019) Osservatorio Nazionale sull\u2019Impiego dei Farmaci. L\u2019uso dei farmaci in Italia. Rapporto Nazionale. Anno.\u00a0\u00a0https:\/\/www.epicentro.iss.it\/farmaci\/OsMed.\u00a0Accessed 10 Aug 2023"},{"key":"7493_CR32","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/head.12164","volume":"53","author":"D Serrano","year":"2013","unstructured":"Serrano D et al (2013) Effects of switching acute treatment on disability in migraine patients using triptans. Headache 53:1415\u20131429","journal-title":"Headache"},{"key":"7493_CR33","first-page":"255","volume":"22","author":"M Levi","year":"2016","unstructured":"Levi M et al (2016) Patient adherence to olmesartan\/amlodipine combinations: fixed versus extemporaneous combinations. J Manag Care Spec Pharm 22:255\u2013262","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07493-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07493-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07493-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T10:29:02Z","timestamp":1723026542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07493-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7493"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07493-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IQVIA LPD data relies on anonymous data which are not originated by any clinical trial. A non-identifiable encryption process guarantee data are anonymized before being stored into IQVIA databases, directly on GPs\u2019 computer. IQVIA LPD complies with the European Regulation 679\/2016 and the ex-Legislative Decree 196\/03 and subsequent modifications, and all the analyses using IQVIA LPD data do not require any Ethical Committee\u2019s approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"S.D.C. and R.D.V. have disclosed that they are employees of Pfizer Srl. V.P. has disclosed that she is an employee of IQVIA. S.S.: personal fees as speaker or advisor (Abbott, Allergan-Abbvie, AstraZeneca, Boheringer, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Pfizer, Teva); research grants (Novartis, Uriach); intellectual (president elect European Stroke Organization, second vice president of the European Headache Federation, specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology, associate editor for The Journal of Headache and Pain, assistant editor for Stroke). R.O.: personal fees as speaker or advisor (Allergan-AbbVie, Eli Lilly, Novartis, Pfizer, Teva); research grants (Novartis); intellectual (Associate Editor in Headache and Neurogenic Pain for Frontiers in Neurology, Junior Editorial Board Member for The Journal of Headache and Pain).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}